Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

Research output: Contribution to journalArticlepeer-review


  • M H Cullen
  • C M Woodroffe
  • A D Chetiyawardana
  • N H Gower
  • R Joshi
  • R M Rudd
  • S G Spiro
  • J E Cook
  • C Trask
  • E Bessell
  • C K Connolly
  • J Tobias
  • R L Souhami


Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.


Original languageEnglish
Pages (from-to)3188-94
Number of pages7
JournalJournal of Clinical Oncology
Issue number10
Publication statusPublished - Oct 1999


  • Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Ifosfamide, Lung Neoplasms, Male, Middle Aged, Mitomycin, Prognosis, Quality of Life, Survival Analysis